RJA
APEN

Raymond James & Associates’s Apollo Endosurgery, Inc. APEN Stock Holding History

Raymond James & Associates’s Portfolio APEN Stock Details APEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-28,392
Closed -$257K – 4327
2021
Q3 		$257K Buy
+28,392
New +$244K ﹤0.01% 3522

Other funds holding APEN

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
PGM
Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Raymond James & Associates's APEN Position: Q4 2021 in Review

Raymond James & Associates sold out of Apollo Endosurgery, Inc. (APEN) in Q4 2021, closing a stake of 28,392 shares — an estimated $257K sold.

Raymond James & Associates first reported a position in APEN in Q3 2021 and held it in 1 quarter. The position peaked at $257K in Q3 2021. 72 funds tracked by Wall St. Rank hold APEN as of Q4 2021.

  • Raymond James & Associates reported no remaining Apollo Endosurgery, Inc. position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 28,392 Apollo Endosurgery, Inc. shares in Q4 2021, an estimated $257K.
  • Raymond James & Associates first reported a position in Apollo Endosurgery, Inc. in Q3 2021 and held it in 1 quarter.
  • Raymond James & Associates's Apollo Endosurgery, Inc. position peaked at $257K in Q3 2021.
  • 72 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.